One specific metabolic alteration that results from functional deficiency of FMRP in FXS individuals is the reduction in serum cholesterol [3,4], which potentially could identify a useful target for possible therapy in metabolic disease. This evidence concerns the gene FMR1 and fragile X syndrome.